RU2015115327A - USE OF YB-1 PROTEIN AND ITS FRAGMENTS FOR THE PRODUCTION OF MEDICINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE - Google Patents
USE OF YB-1 PROTEIN AND ITS FRAGMENTS FOR THE PRODUCTION OF MEDICINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE Download PDFInfo
- Publication number
- RU2015115327A RU2015115327A RU2015115327A RU2015115327A RU2015115327A RU 2015115327 A RU2015115327 A RU 2015115327A RU 2015115327 A RU2015115327 A RU 2015115327A RU 2015115327 A RU2015115327 A RU 2015115327A RU 2015115327 A RU2015115327 A RU 2015115327A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- protein
- amino acid
- acid sequence
- rabbit
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title claims abstract 9
- 239000003814 drug Substances 0.000 title claims abstract 5
- 238000004519 manufacturing process Methods 0.000 title claims abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims abstract 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 12
- 102000004169 proteins and genes Human genes 0.000 claims abstract 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract 6
- 230000002159 abnormal effect Effects 0.000 claims abstract 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract 4
- 230000002708 enhancing effect Effects 0.000 claims abstract 4
- 230000004770 neurodegeneration Effects 0.000 claims abstract 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 4
- 230000016273 neuron death Effects 0.000 claims abstract 4
- 238000001243 protein synthesis Methods 0.000 claims abstract 4
- 230000014616 translation Effects 0.000 claims abstract 4
- 239000003085 diluting agent Substances 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 239000012528 membrane Substances 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 230000002265 prevention Effects 0.000 claims abstract 2
- 229940124597 therapeutic agent Drugs 0.000 claims abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 108010048626 Y-Box-Binding Protein 1 Proteins 0.000 abstract 6
- 102100022224 Y-box-binding protein 1 Human genes 0.000 abstract 6
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Применение полноразмерного белка YB-1, который имеет аминокислотную последовательность человека SEQ ID NO: 1 или кролика SEQ ID NO: 7, или активного фрагмента белка YB-1, который имеет аминокислотную последовательность человека SEQ ID NO: 3 или кролика SEQ ID NO: 9, или активного фрагмента белка YB-1, который имеет аминокислотную последовательность человека SEQ ID NO: 5 или кролика SEQ ID NO: 11, для изготовления лекарственного средства для лечения и/или профилактики нейродегенеративных заболеваний с ненормальным синтезом белка и гибелью нейронов у субъекта за счет снижения уровня мозгового β-амилоида.2. Фармацевтическая композиция для лечения и/или профилактики нейродегенеративных заболеваний с ненормальным синтезом белка и гибелью нейронов у субъекта, содержащая эффективное количество полноразмерного белка YB-1,который имеет аминокислотную последовательность человека SEQ ID NO: 1 или кролика SEQ ID NO: 7, или активного фрагмента белка YB-1, который имеет аминокислотную последовательность человека SEQ ID NO: 3 или кролика SEQ ID NO: 9, или активного фрагмента белка YB-1, который имеет аминокислотную последовательность человека SEQ ID NO: 5 или кролика SEQ ID NO: 11 и фармацевтически приемлемый носитель, который выбирают из группы состоящей из разбавителя, агента повышающего назальную доставку белка, агента способствующего проникновению белка через мембраны, агента улучшающего стабильность белка терапевтического агента или их комбинации.1. The use of a full-sized protein YB-1, which has the amino acid sequence of a human SEQ ID NO: 1 or rabbit SEQ ID NO: 7, or an active fragment of the protein YB-1, which has the amino acid sequence of a human SEQ ID NO: 3 or rabbit SEQ ID NO : 9, or an active fragment of YB-1 protein that has the human amino acid sequence of SEQ ID NO: 5 or rabbit SEQ ID NO: 11, for the manufacture of a medicament for the treatment and / or prevention of neurodegenerative diseases with abnormal protein synthesis and neuronal death in a subject due to bottom eniya of brain β-amiloida.2. A pharmaceutical composition for treating and / or preventing neurodegenerative diseases with abnormal protein synthesis and neuronal death in a subject, comprising an effective amount of a full-length YB-1 protein that has the human amino acid sequence of SEQ ID NO: 1 or rabbit SEQ ID NO: 7, or an active fragment protein YB-1, which has the amino acid sequence of a human SEQ ID NO: 3 or rabbit SEQ ID NO: 9, or an active fragment of the protein YB-1, which has the amino acid sequence of a human SEQ ID NO: 5 or rabbit SEQ ID NO: 11 and f an pharmaceutically acceptable carrier selected from the group consisting of a diluent, a nasal protein delivery enhancing agent, a membrane penetrating protein promoter, a protein stability enhancing therapeutic agent, or a combination thereof.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2015115327A RU2015115327A (en) | 2015-04-24 | 2015-04-24 | USE OF YB-1 PROTEIN AND ITS FRAGMENTS FOR THE PRODUCTION OF MEDICINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2015115327A RU2015115327A (en) | 2015-04-24 | 2015-04-24 | USE OF YB-1 PROTEIN AND ITS FRAGMENTS FOR THE PRODUCTION OF MEDICINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013139704/15A Substitution RU2561050C2 (en) | 2013-08-28 | 2013-08-28 | Application of protein yb-1 and its fragments for production of medications in treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015115327A true RU2015115327A (en) | 2016-11-20 |
Family
ID=57759461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015115327A RU2015115327A (en) | 2015-04-24 | 2015-04-24 | USE OF YB-1 PROTEIN AND ITS FRAGMENTS FOR THE PRODUCTION OF MEDICINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2015115327A (en) |
-
2015
- 2015-04-24 RU RU2015115327A patent/RU2015115327A/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ibraheem et al. | Administration strategies for proteins and peptides | |
| MX2021002321A (en) | Novel methods. | |
| ES2925550T3 (en) | neurodegenerative disorders | |
| WO2015037248A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| BR112015010396A2 (en) | combination therapy | |
| EA201490279A1 (en) | KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE | |
| IN2014DN05670A (en) | ||
| UA107578C2 (en) | COMBINED DIABETES THERAPY | |
| EA201490163A1 (en) | KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE | |
| EA201490277A1 (en) | KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE | |
| MX2017012506A (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF EYE DISEASES CONTAINING, AS ACTIVE INGREDIENT, A FUSION PROTEIN IN WHICH THE PEPTIDE THAT PENETRATES THE TISSUE AND THE PREPARATION OF THE ANTI-ASCULAR ENDOTELIAL GROWTH FACTOR IS FUSED. | |
| MA40057A (en) | Therapeutic tratment of skin disease with recombinant commensal skin microorganisms | |
| WO2016090024A3 (en) | Combination therapy for treatment of cancer | |
| EA201171087A1 (en) | METHODS OF ADMINISTRATION (4aR, 10aR) -1-n-PROPIL-1,2,3,4,4a, 5,10,10a-OCTAGHYDROBENZO [g] KHINOLIN-6,7-DIOLA AND RELATED COMPOUNDS THROUGH THE IMMABLE SHELL OF THE CAVITY SLIM OF THE NOSE OR SKIN AND PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS | |
| IN2014DN06920A (en) | ||
| WO2013173827A3 (en) | Methods and compositions for inhibiting diseases of the central nervous system | |
| EA201490750A1 (en) | USING GLUTHARILHYSTAMINE FOR THE TREATMENT OF RESPIRATORY DISEASES | |
| MX2021012579A (en) | Collagen peptide-based medicament compositions and devices and methods of production and use thereof. | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| MX2021011269A (en) | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine. | |
| PH12021552358A1 (en) | Compounds and compositions as modulators of tlr signaling | |
| RU2017126212A (en) | COMPOSITION | |
| EA202090802A1 (en) | PEPTIDE COMPOSITION FOR TREATMENT OF DAMAGE ASSOCIATED WITH EXCITING NEUROTOXICITY | |
| BR112015012497A2 (en) | pharmaceutical combinations | |
| RU2015115327A (en) | USE OF YB-1 PROTEIN AND ITS FRAGMENTS FOR THE PRODUCTION OF MEDICINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170227 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20170227 |
|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170719 |